The Food and Drug Administration today withdrew approval for Makena and its generics, citing a confirmatory study that did not verify clinical benefit. Makena had been approved under the FDA’s accelerated approval pathway to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. Makena and its generics cannot lawfully be distributed in interstate commerce, effective immediately. FDA is aware that some products have already been distributed, so health care providers should talk to their patients, if applicable.

Related News Articles

Headline
The Senate Health, Education, Labor and Pensions Committee today voted 14-7 to advance as amended to the full Senate the Bipartisan Primary Care and Health…
Headline
The U.S. infant mortality rate was essentially unchanged in 2021, but the number of deaths rose 2% to 19,928, the Centers for Disease Control and Prevention…
Headline
Based on an AHA-led discussion with hospital leaders, this resource shares strategies to foster equitable practices in maternal care at the patient and…
Headline
A new report from the National Academies of Sciences, Engineering, and Medicine recommends actions to improve access to pediatric subspecialty care. The report…
Headline
The Centers for Disease Control and Prevention Sept. 5 alerted clinicians to a recent increase in respiratory syncytial virus in the Southeastern U.S.,…
Headline
The Centers for Medicare & Medicaid Services sent to each state letters regarding compliance with federal requirements related to automatic eligibility…